M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John de Groot,Kathleen R. Lamborn,Susan M. Chang,Mark R. Gilbert,Timothy F. Cloughesy,Kenneth Aldape,Jun Yao,Edward F. Jackson,Frank S. Lieberman,H. Ian Robins,Minesh P. Mehta,Andrew B. Lassman,Lisa M. DeAngelis,W. K. Alfred Yung,Alice P. Chen,Michael D. Prados,Patrick Y. Wen +16 more
TL;DR: Aflibercept monotherapy has moderate toxicity and minimal evidence of single-agent activity in unselected patients with recurrent malignant glioma.
Journal ArticleDOI
Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme
TL;DR: Treatment with TMZ was associated with improvement in HRQOL scores compared with treatment with PCB, and delaying disease progression by treatment with TMZ is beneficial to theHRQOL status of patients with recurrent GBM.
Journal ArticleDOI
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
Fabio M. Iwamoto,Kathleen R. Lamborn,H. Ian Robins,Minesh P. Mehta,Susan M. Chang,Nicholas Butowski,Lisa M. DeAngelis,Lauren E. Abrey,Wei-Ting Zhang,Michael D. Prados,Howard A. Fine +10 more
TL;DR: Pazopanib did not prolong PFS in this patient population but showed in situ biological activity as demonstrated by radiographic responses and was reasonably well tolerated with a spectrum of toxicities similar to other anti-VEGF/VEGFR agents.
Journal ArticleDOI
Gene expression and angiotropism in primary CNS lymphoma
James L. Rubenstein,Jane Fridlyand,Arthur Shen,Kenneth Aldape,David G. Ginzinger,Tracy T. Batchelor,Patrick A. Treseler,Mitchel S. Berger,Michael T. McDermott,Michael D. Prados,Jon Karch,Craig Okada,William C. Hyun,Seema Parikh,Christopher M. Haqq,Marc A. Shuman +15 more
TL;DR: It is demonstrated that interleukin-4 (IL-4) is expressed by tumor vasculature as well as by tumor cells in CNS lymphomas, and high expression of activated STAT6 in tumors was associated with short survival in an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous methotrexate therapy.
Journal ArticleDOI
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma
Christopher E. Pelloski,Edward H. Lin,Li Zhang,W. K. Alfred Yung,Howard Colman,Juinn Lin Liu,S.Y. Woo,Amy B. Heimberger,Dima Suki,Michael D. Prados,Susan M. Chang,Fredrick G. Barker,Gregory N. Fuller,Kenneth Aldape +13 more
TL;DR: Elevated expression of p-MAPK is associated with increased radiation resistance and represents an independent prognostic factor in these tumors and p- MAPK and activated members of the Akt pathway are markers of outcome in glioblastoma.